An update on PET-based molecular imaging in neuro-oncology: challenges and implementation for a precision medicine approach in cancer care

Hossein Shooli; Habibollah Dadgar; Yì-Xiáng J Wáng; Manochehr Seyedi Vafaee; Saman Rassaei Kashuk; Reza Nemati; Esmail Jafari; Iraj Nabipour; Ali Gholamrezanezhad; Majid Assadi; Mykol Larvie

doi:10.21037/qims.2019.08.16

An update on PET-based molecular imaging in neuro-oncology: challenges and implementation for a precision medicine approach in cancer care

Hossein Shooli, Habibollah Dadgar, Yì-Xiáng J Wáng, Manochehr Seyedi Vafaee, Saman Rassaei Kashuk, Reza Nemati, Esmail Jafari, Iraj Nabipour, Ali Gholamrezanezhad, Majid Assadi, Mykol Larvie

Research output: Contribution to journal › Journal article › Research › peer-review

Abstract

PET imaging using novel radiotracers show promises for tumor grading and molecular characterization through visualizing molecular and functional properties of the tumors. Application of PET tracers in brain neoplasm depends on both type of the neoplasm and the research or clinical significance required to be addressed. In clinical neuro-oncology, 18F-FDG is used mainly to differentiate tumor recurrence from radiation-induced necrosis, and novel PET agents show attractive imaging properties. Novel PET tracers can offer biologic information not visible via contrast-enhanced MRI or 18F-FDG PET. This review aims to provide an update on the complementary role of PET imaging in neuro-oncology both in research and clinical settings along with presenting interesting cases in this context.

Original language	English
Journal	Quantitative imaging in medicine and surgery
Volume	9
Issue number	9
Pages (from-to)	1597-1610
ISSN	2223-4292
DOIs	https://doi.org/10.21037/qims.2019.08.16
Publication status	Published - Sept 2019

Keywords

68Ga-DOTA-peptide
68Ga-labeled PSMA
Brain tumors
Magnetic resonance imaging (MRI)
Molecular imaging
Positron emission tomography (PET)
Precision medicine

Documents & Links

10.21037/qims.2019.08.16

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6785513/pdf/qims-09-09-1597.pdf

SDU Link

Check access to the material in SDU Library's search engine

Cite this

Shooli, H., Dadgar, H., Wáng, Y.-X. J., Vafaee, M. S., Kashuk, S. R., Nemati, R., Jafari, E., Nabipour, I., Gholamrezanezhad, A., Assadi, M., & Larvie, M. (2019). An update on PET-based molecular imaging in neuro-oncology: challenges and implementation for a precision medicine approach in cancer care. Quantitative imaging in medicine and surgery, 9(9), 1597-1610. https://doi.org/10.21037/qims.2019.08.16

@article{7ed3296267d24b30af0d2bac9b34facd,

title = "An update on PET-based molecular imaging in neuro-oncology: challenges and implementation for a precision medicine approach in cancer care",

abstract = "PET imaging using novel radiotracers show promises for tumor grading and molecular characterization through visualizing molecular and functional properties of the tumors. Application of PET tracers in brain neoplasm depends on both type of the neoplasm and the research or clinical significance required to be addressed. In clinical neuro-oncology, 18F-FDG is used mainly to differentiate tumor recurrence from radiation-induced necrosis, and novel PET agents show attractive imaging properties. Novel PET tracers can offer biologic information not visible via contrast-enhanced MRI or 18F-FDG PET. This review aims to provide an update on the complementary role of PET imaging in neuro-oncology both in research and clinical settings along with presenting interesting cases in this context.",

keywords = "68Ga-DOTA-peptide, 68Ga-labeled PSMA, Brain tumors, Magnetic resonance imaging (MRI), Molecular imaging, Positron emission tomography (PET), Precision medicine",

author = "Hossein Shooli and Habibollah Dadgar and W{\'a}ng, \{Y{\`i}-Xi{\'a}ng J\} and Vafaee, \{Manochehr Seyedi\} and Kashuk, \{Saman Rassaei\} and Reza Nemati and Esmail Jafari and Iraj Nabipour and Ali Gholamrezanezhad and Majid Assadi and Mykol Larvie",

year = "2019",

month = sep,

doi = "10.21037/qims.2019.08.16",

language = "English",

volume = "9",

pages = "1597--1610",

journal = "Quantitative imaging in medicine and surgery",

issn = "2223-4292",

publisher = "AME Publishing Company",

number = "9",

}

Shooli, H, Dadgar, H, Wáng, Y-XJ, Vafaee, MS, Kashuk, SR, Nemati, R, Jafari, E, Nabipour, I, Gholamrezanezhad, A, Assadi, M & Larvie, M 2019, 'An update on PET-based molecular imaging in neuro-oncology: challenges and implementation for a precision medicine approach in cancer care', Quantitative imaging in medicine and surgery, vol. 9, no. 9, pp. 1597-1610. https://doi.org/10.21037/qims.2019.08.16

An update on PET-based molecular imaging in neuro-oncology: challenges and implementation for a precision medicine approach in cancer care. / Shooli, Hossein; Dadgar, Habibollah; Wáng, Yì-Xiáng J et al.
In: Quantitative imaging in medicine and surgery, Vol. 9, No. 9, 09.2019, p. 1597-1610.

Research output: Contribution to journal › Journal article › Research › peer-review

TY - JOUR

T1 - An update on PET-based molecular imaging in neuro-oncology

T2 - challenges and implementation for a precision medicine approach in cancer care

AU - Shooli, Hossein

AU - Dadgar, Habibollah

AU - Wáng, Yì-Xiáng J

AU - Vafaee, Manochehr Seyedi

AU - Kashuk, Saman Rassaei

AU - Nemati, Reza

AU - Jafari, Esmail

AU - Nabipour, Iraj

AU - Gholamrezanezhad, Ali

AU - Assadi, Majid

AU - Larvie, Mykol

PY - 2019/9

Y1 - 2019/9

N2 - PET imaging using novel radiotracers show promises for tumor grading and molecular characterization through visualizing molecular and functional properties of the tumors. Application of PET tracers in brain neoplasm depends on both type of the neoplasm and the research or clinical significance required to be addressed. In clinical neuro-oncology, 18F-FDG is used mainly to differentiate tumor recurrence from radiation-induced necrosis, and novel PET agents show attractive imaging properties. Novel PET tracers can offer biologic information not visible via contrast-enhanced MRI or 18F-FDG PET. This review aims to provide an update on the complementary role of PET imaging in neuro-oncology both in research and clinical settings along with presenting interesting cases in this context.

AB - PET imaging using novel radiotracers show promises for tumor grading and molecular characterization through visualizing molecular and functional properties of the tumors. Application of PET tracers in brain neoplasm depends on both type of the neoplasm and the research or clinical significance required to be addressed. In clinical neuro-oncology, 18F-FDG is used mainly to differentiate tumor recurrence from radiation-induced necrosis, and novel PET agents show attractive imaging properties. Novel PET tracers can offer biologic information not visible via contrast-enhanced MRI or 18F-FDG PET. This review aims to provide an update on the complementary role of PET imaging in neuro-oncology both in research and clinical settings along with presenting interesting cases in this context.

KW - 68Ga-DOTA-peptide

KW - 68Ga-labeled PSMA

KW - Brain tumors

KW - Magnetic resonance imaging (MRI)

KW - Molecular imaging

KW - Positron emission tomography (PET)

KW - Precision medicine

U2 - 10.21037/qims.2019.08.16

DO - 10.21037/qims.2019.08.16

M3 - Journal article

C2 - 31667145

SN - 2223-4292

VL - 9

SP - 1597

EP - 1610

JO - Quantitative imaging in medicine and surgery

JF - Quantitative imaging in medicine and surgery

IS - 9

ER -

An update on PET-based molecular imaging in neuro-oncology: challenges and implementation for a precision medicine approach in cancer care

Abstract

Keywords

Documents & Links

SDU Link

Fingerprint

Cite this